TR201813644T1 - Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. - Google Patents
Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. Download PDFInfo
- Publication number
- TR201813644T1 TR201813644T1 TR2018/13644A TR201813644A TR201813644T1 TR 201813644 T1 TR201813644 T1 TR 201813644T1 TR 2018/13644 A TR2018/13644 A TR 2018/13644A TR 201813644 A TR201813644 A TR 201813644A TR 201813644 T1 TR201813644 T1 TR 201813644T1
- Authority
- TR
- Turkey
- Prior art keywords
- prostate
- endoradiotherapy
- specific membrane
- membrane antigen
- prostate cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar açıklanmaktadır.
Description
Tarifname ile belgeye dahil edilen referanslar arasindaki herhangi bir tutarsizlik halinde, tarifname (dahil edilmis referansa dayali olabilecek ilgili tadiller dahil) geçerli olacaktir. Aksi belirtilmedikçe, terimler burada alanda kabul edilen standart anlamlariyla kullanilmaktadir. Burada çesitli terimler için standart kisaltmalar kullanilmaktadir. M.G., Ray, S., Mease, R.C., Foss, C. Prostat-spesifik membran antijenin (PSMA) etiketlenmis inhibitörleri, biyolojik degerlendirme ve görüntüleme ajanlarinin kullanimi hakkinda, yayin tarihi: 31/; Chandran S.S., Ray S., Denmeade S.R., Pomper M.G., Mease R.C., Prostat kanserinin tedavisi için prostat-spesifik membran antijen hedefli nanopartiküller hakkinda, yayin M.G., Mease R.C.; Ray S., Chen Y. PSMA hedefli bilesikler ve bunlarin kullanimlari hakkinda, yayin tarihi: 23/; Banerjee, S. R., Foss, C. A., Pullambhatla, M., Wang, Y., Srinivasan, S., Hobbs, R. F., Baidoo, K. E., Brechbiel, M. W., Nimmagadda, S., Mease, R. C., Sgouros, G. Ve Pomper, M. G. (2015) Dozametre tahminleri bakimindan prostat- Spesifik membran anti Jenin 86Y -etiketli inhibitörlerinin klinik öncesi degerlendirmesi. Journal of nuclear medicine 56, 628-34; Benesova, M., Schafer, M., Bauder-Wust, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., ve Eder, M. (2015) Prostat Kanserinin Görüntülenmesi ve Endoradyoterapisi için Optimize edilmis Baglayici Parçaya sahip Özel olarak Hazirlanmis DOTA-Konjüge PSMA Inhibitörünün Klinik öncesi Degerlendirmesi. Journal of nuclear medicine 56, 914-20; Tykvart, J., Schimer, J., Jancarik, A., Barinkova, J., Navratil, V., Starkova, J., Sramkova, K., Konvalinka, J., Majer, P., ve Sacha, P. (2015) Glütamat Karboksipeptidaz için Seçilmis Yüksek Etkili Üre Bazli Ekzositoz Baglama Weineisen, M., Simecek, J., Schottelius, M., Schwaiger, M. ve Wester, H.-J. (2014) Prostat kanserinin fonkSIy0nel görüntülenmesi ve endoradyoterapisi için DOTAGA-konjüge PSMA ligantlarinin sentezi ve klinik öncesi degerlendirmesi. EJNMMI Res 4,1-15. Yukaridaki bulusun konusu, daha net anlasilmasi için resimler ve örneklerle ayrintili sekilde açiklanmis olsa da, alanda bilgi sahibi kisiler ekteki istemlerin kapsaminda belirli degisiklikler ve tadiller yapilabilecegini anlayacaktir. TR TR TR TR TR TR TR TR TR TR TR
Claims (1)
1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201813644T1 true TR201813644T1 (tr) | 2018-11-21 |
Family
ID=59899817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/13644A TR201813644T1 (tr) | 2016-03-22 | 2017-03-22 | Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (tr) |
| EP (3) | EP4385981A1 (tr) |
| JP (3) | JP7073270B2 (tr) |
| KR (4) | KR20220063298A (tr) |
| CN (3) | CN120172884A (tr) |
| AU (1) | AU2017238181B2 (tr) |
| BR (1) | BR112018069507A2 (tr) |
| CA (1) | CA3018709A1 (tr) |
| CL (1) | CL2018002683A1 (tr) |
| CY (1) | CY1124487T1 (tr) |
| DK (2) | DK3433238T3 (tr) |
| ES (2) | ES2972148T3 (tr) |
| FI (1) | FI3925952T3 (tr) |
| HR (2) | HRP20240215T1 (tr) |
| HU (2) | HUE055607T2 (tr) |
| LT (2) | LT3925952T (tr) |
| MX (1) | MX384823B (tr) |
| PH (1) | PH12018502048A1 (tr) |
| PL (2) | PL3925952T3 (tr) |
| PT (2) | PT3925952T (tr) |
| RS (2) | RS65188B1 (tr) |
| RU (2) | RU2749399C2 (tr) |
| SA (1) | SA518400103B1 (tr) |
| SI (2) | SI3433238T1 (tr) |
| TR (1) | TR201813644T1 (tr) |
| WO (1) | WO2017165473A1 (tr) |
| ZA (1) | ZA201806389B (tr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803973B (zh) | 2016-08-10 | 2022-05-24 | 癌靶技术有限责任公司 | 螯合psma抑制剂 |
| CA3043619A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
| ES2972577T3 (es) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP) |
| US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| TN2020000072A1 (en) * | 2017-12-11 | 2022-01-06 | Univ Muenchen Tech | Psma ligands for imaging and endoradiotherapy |
| SI3498308T1 (sl) * | 2017-12-13 | 2025-03-31 | Sciencons AS | Kompleks, ki obsega PSMA-ciljajočo spojino, vezano na svinčev ali torijev radionuklid |
| CN118146196A (zh) * | 2018-02-06 | 2024-06-07 | 海德堡大学 | Fap抑制剂 |
| CA3090495A1 (en) | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| WO2019190266A1 (ko) * | 2018-03-30 | 2019-10-03 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| CA3098492A1 (en) * | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| EP4473980A3 (en) * | 2018-09-28 | 2025-05-14 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| US20220273826A1 (en) * | 2019-07-02 | 2022-09-01 | Novartis Ag | Prostate specific membrane antigen (psma) ligands and uses thereof |
| PH12021553284A1 (en) * | 2019-07-02 | 2022-08-01 | Advanced Accelerator Applications Italy Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| US20230330278A1 (en) * | 2020-04-29 | 2023-10-19 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230406847A1 (en) | 2020-11-12 | 2023-12-21 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| CN116438190A (zh) * | 2020-11-19 | 2023-07-14 | 诺华股份有限公司 | 前列腺特异性膜抗原(psma)配体的合成 |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| JP2024523344A (ja) * | 2021-06-17 | 2024-06-28 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 生物製剤を複数のキレーターと組み合わせるための方法及び材料 |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| JP2025506001A (ja) | 2022-02-09 | 2025-03-05 | ノバルティス アーゲー | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
| EP4637843A2 (en) * | 2022-12-21 | 2025-10-29 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044468B2 (en) | 2007-06-26 | 2015-06-02 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| AU2009322171A1 (en) | 2008-12-05 | 2011-06-30 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| HUE068042T2 (hu) | 2009-03-19 | 2024-12-28 | Univ Johns Hopkins | PSMA-targetáló vegyületek és alkalmazásaik |
| US8926944B2 (en) * | 2011-08-05 | 2015-01-06 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| CN113149921B (zh) * | 2011-11-30 | 2024-11-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| ES2738474T3 (es) * | 2013-01-14 | 2020-01-23 | Molecular Insight Pharm Inc | Radiofármacos a base de triazina y agentes radioimagenológicos |
| TN2016000137A1 (en) * | 2013-10-18 | 2017-10-06 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3536345A1 (en) * | 2014-05-06 | 2019-09-11 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| WO2016030329A1 (en) * | 2014-08-24 | 2016-03-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| WO2016065435A2 (en) * | 2014-10-30 | 2016-05-06 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active Search and Examination
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201813644T1 (tr) | Prostat kanserinin endoradyoterapisi için prostat-spesifik membran antijen hedefli yüksek afiniteli ajanlar. | |
| BR112023015045A2 (pt) | Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| MY197061A (en) | Improved 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| Hoerr et al. | Magnetic resonance imaging characterization of microbial infections | |
| EP3954296A4 (en) | X-RAY IMAGING APPARATUS AND X-RAY IMAGING SYSTEM | |
| EP3367667A4 (en) | IMAGING DEVICE, ENDOSCOPE AND ENDOSCOPE SYSTEM | |
| MX386900B (es) | Compuestos para formacion de imagenes de agregados de proteinas tau. | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| EP3634236A4 (en) | Systems and methods for medical imaging | |
| CY1124397T1 (el) | Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου | |
| BR112018012660A2 (pt) | composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo | |
| EP3410691A4 (en) | IMAGING UNIT, IMAGE MODULE AND ENDOSCOPE | |
| Saidlitz et al. | Amyloid imaging in Alzheimer's disease: a literature review | |
| EP3476293A4 (en) | MOBILE X-RAY IMAGING DEVICE | |
| Osório et al. | Cat-scratch disease during anti-tumor necrosis factor-alpha therapy: case report and review of the literature | |
| Ko et al. | Achieving high-quality surgical care: observations from the American College of Surgeons Quality of Care Programs | |
| Jordana-Garcia | Optimised diagnosis in digital flexor tendon sheath pathology in the horse | |
| Bendyuk et al. | Izuchenie potrebnosti v meditsinskoy pomoshchi u rabotnikov promyshlennogo predpriyatiya | |
| van Gelderen et al. | Exploring a flexible pulse design for studying magnetization transfer | |
| 한진 et al. | An Investigation on the Human Error of Medical Imaging in Mass Media | |
| MX388833B (es) | Compuesto marcado con 18f para diagnostico de cancer de prostata y uso de este | |
| Yoo | The Social Stress-Buffering Role of Exchanging Emotional Support in an Online Breast Cancer Support Group | |
| Cencini et al. | Primary nasopharyngeal Hodgkin lymphoma |